12 results about "Cancer imaging" patented technology

The invention discloses a cathepsin B activated chemiluminescent nanoparticle. The cathepsin B activated chemiluminescent nanoparticle is prepared from cat B-C-550, hypericin and DSPE-mPEG2000 (Distearoyl Phosphate Polyethylene-mPEG (Polyethylene Glycol) 2000 in a self-assembly manner; the structure of the cat B-C-550 is as shown in a formula I in the specification. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of reagents or drugs for screening or diagnosing tumors. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of a cancer imaging reagent and / or a medicine for treating tumors. According to the invention, chemiluminescence imaging and in-situ cancer PDT treatment without external exciting light are realized. The cat B enzyme response type chemiluminescent nanoparticles are high in stability and can be effectively targeted and enriched at tumor focus parts.

The present disclosure provides technologies that allow reduced field of view or fast imaging with reduced image distortion. The first technique capitalizes on the benefit of reduced field of view imaging for full field of view coverage. The second technique allows achieves high resolution 3D images in a focused region. These techniques are expected to have applications for cancer imaging, neuro imaging, and other biomedical imaging areas.

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging / diagnostic agents.

The application relates to the technical field of image processing, in particular to a cancer image processing method and system based on a Mamba structure and a medium, the method comprising the following steps: marking a lesion area and grading in an MRI image; performing pretreatment and image expansion processing on the MRI image to form a sample data set containing multiple image modalities; extracting multi-scale features of each image modality through an improved neural network model; feeding the multi-scale features through each Mamba block and a corresponding down-sampling layer to obtain modality output features; performing multi-task learning through a multi-task learning module to obtain a multi-task learning loss; updating parameters of the improved neural network model according to the multi-task learning loss to obtain a trained model; inputting newly collected MRI images into the trained model to obtain a lesion positioning result of a cancer image and a classification result of the cancer image; and the application can improve the detection and classification performance and efficiency of the cancer image.

A technology is described which provides a platform for improving the penetration into tumors in a subject of cancer treatment and cancer imaging agents for greater patient benefit. The invention in particular overcomes two challenges for use of tumor targeting methods for solid tumors: poor penetration and the immunosuppressive nature of the tumor microenvironment. The platform described here allows long-term, in vivo production of iRGD. In a preferred embodiment, CAR-T cells are engineered to secrete iRGD, a tumor-penetrating peptide to achieve tissue-penetrating delivery of drugs and imaging agents in a tumor-specific manner. The peptide acutely permeabilizes the tumor vasculature by binding to αv integrins and neuropilin, but in a tumor-specific manner. This method produces a modification in the tumor microenvironment that enhances drug access into the tumor, prevents distant metastasis of the tumor cells, and allows long-term iRGD therapy without the need for repeated injections of iRGD.

To provide improved radiopharmaceuticals and radiodiagnostics, in particular in the field of cancer, including improvements in pharmacokinetic properties.SOLUTION: The present invention relates to a compound binding to an endogenous receptor, the compound comprising (i) an oligopeptide comprising a dipeptide with Trp being the C-terminal amino acid of the dipeptide, wherein the Trp is replaced with an α-amino acid Xaa2, whereby the stability in serum or plasma of the peptide bond connecting Xaa2 to the N-terminally adjacent amino acid is increased as compared to the peptide bond connecting Trp to the N-terminally adjacent amino acid in an otherwise identical compound; and (ii) a moiety capable of generating therapeutically effective radiation, the moiety being covalently bound to the oligopeptide.SELECTED DRAWING: Figure 12

The present invention relates to modified GRPR antagonist peptides for use in cancer imaging and treatment. The present application relates to a compound that binds to an endogenous receptor, said compound comprising (i) an oligopeptide comprising a dipeptide having a Trp as the C-terminal amino acid of said dipeptide, where said Trp is replaced by an alpha-amino acid Xaa2, whereby the Trp is more than the N-terminal adjacent amino acid in a peptide bond linking the Trp to the N-terminal adjacent amino acid in an otherwise identical compound. The stability of a peptide bond connecting Xaa2 and amino acid adjacent to the N terminal in serum or plasma is improved; and (ii) a moiety capable of generating therapeutically effective radiation, the moiety covalently bound to the oligopeptide.

The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, and salivary glands, which represent sites of off-target binding and toxicity for PSMA-targeted prostate cancer imaging agents and therapies. Accordingly, the 2-PMPA prodrugs can be used to pretreat, bind to, and shield the kidney and salivary glands from PSMA-targeted cytotoxic or radiotherapy.

The disclosure relates to double halogenated phenylalanine derivatives, which can be radiolabeled with PET or SPECT radioisotopes, and their use in treating and / or imaging cancer.

The present invention relates to modified GRPR antagonist peptides for use in cancer imaging and treatment. The present application relates to a compound that binds to an endogenous receptor, said compound comprising (i) an oligopeptide comprising a dipeptide having a Trp as the C-terminal amino acid of said dipeptide, where said Trp is replaced by an alpha-amino acid Xaa2, whereby the Trp is more than the N-terminal adjacent amino acid in a peptide bond linking the Trp to the N-terminal adjacent amino acid in an otherwise identical compound. The stability of a peptide bond connecting Xaa2 and amino acid adjacent to the N terminal in serum or plasma is improved; and (ii) a moiety capable of generating therapeutically effective radiation, the moiety covalently bound to the oligopeptide.

The present invention relates to modified GRPR antagonist peptides for use in cancer imaging and treatment. The present application relates to a compound that binds to an endogenous receptor, said compound comprising (i) an oligopeptide comprising a dipeptide having a Trp as the C-terminal amino acid of said dipeptide, where said Trp is replaced by an alpha-amino acid Xaa2, whereby the Trp is more than the N-terminal adjacent amino acid in a peptide bond linking the Trp to the N-terminal adjacent amino acid in an otherwise identical compound. The stability of a peptide bond connecting Xaa2 and amino acid adjacent to the N terminal in serum or plasma is improved; and (ii) a moiety capable of generating therapeutically effective radiation, the moiety covalently bound to the oligopeptide.

The present application relates to a compound that binds to an endogenous receptor, the compound comprising (i) an oligopeptide comprising a dipeptide having Trp as the C-terminal amino acid of the dipeptide, wherein the Trp is replaced by an alpha-amino acid Xaa2, whereby the stability of the peptide bond connecting Xaa2 to the N-terminally adjacent amino acid is increased in serum or plasma compared to the peptide bond connecting Trp to the N-terminally adjacent amino acid in otherwise identical compounds; and (ii) a moiety capable of producing a therapeutically effective radiation, the moiety being covalently bound to the oligopeptide.